Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Chlamydia trachomatis | glutamine binding protein | 0.0019 | 0 | 0.5 |
Echinococcus multilocularis | GA binding protein alpha chain | 0.0071 | 0.1519 | 0.4188 |
Brugia malayi | Fli-1 protein | 0.0215 | 0.572 | 0.4954 |
Treponema pallidum | amino acid ABC transporter, periplasmic binding protein | 0.0019 | 0 | 0.5 |
Chlamydia trachomatis | arginine ABC transporter substrate-binding protein ArtJ | 0.0019 | 0 | 0.5 |
Mycobacterium ulcerans | glutamine-binding lipoprotein GlnH | 0.0019 | 0 | 0.5 |
Trypanosoma brucei | C-8 sterol isomerase, putative | 0.0362 | 1 | 0.5 |
Treponema pallidum | amino acid ABC transporter, periplasmic binding protein (hisJ) | 0.0019 | 0 | 0.5 |
Loa Loa (eye worm) | fli-1 protein | 0.0215 | 0.572 | 0.5126 |
Echinococcus granulosus | GA binding protein alpha chain | 0.0071 | 0.1519 | 0.4615 |
Loa Loa (eye worm) | hypothetical protein | 0.0185 | 0.4845 | 0.4129 |
Schistosoma mansoni | ets-related | 0.0215 | 0.572 | 1 |
Trypanosoma cruzi | C-8 sterol isomerase, putative | 0.0362 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0362 | 1 | 1 |
Schistosoma mansoni | thyroid hormone receptor | 0.0133 | 0.333 | 0.4312 |
Echinococcus multilocularis | Mitotic checkpoint protein PRCC, C terminal | 0.0123 | 0.3042 | 0.9076 |
Echinococcus granulosus | Mitotic checkpoint protein PRCC C terminal | 0.0123 | 0.3042 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0123 | 0.3042 | 0.3627 |
Loa Loa (eye worm) | D-ets-4 DNA binding domain-containing protein | 0.0071 | 0.1519 | 0.0341 |
Echinococcus multilocularis | thyroid hormone receptor alpha | 0.0133 | 0.333 | 1 |
Mycobacterium tuberculosis | Probable glutamine-binding lipoprotein GlnH (GLNBP) | 0.0019 | 0 | 0.5 |
Schistosoma mansoni | thyroid hormone receptor | 0.0133 | 0.333 | 0.4312 |
Leishmania major | C-8 sterol isomerase-like protein | 0.0362 | 1 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.